PARP1 and cancer: These observations are important because suggest differential therapeutic approaches for these patients: second-generation AR-directed therapies for mCRPC with AR pathway alterations; PI3K inhibitors for a part of patients with cancer-related gene alterations (i.e., PIK3CB-specific inhibitors for patients with alterations of this gene, MEK inhibitors for patients with RAF kinase fusions, and PARP inhibitors for patients with biallelic inactivation of BRCA2, BRCA1, or ATM).